• 1
    Wolfe F. The epidemiology of fibromyalgia. J Musculoskelet Pain 1993; 1: 13748.
  • 2
    Campbell SM, Clark S, Tindall EA et al. Clinical characteristics of fibrositis. I. A ‘blinded’, controlled study of symptoms and tender points. Arthritis Rheum 1983; 26: 81724.
  • 3
    Wolfe F, Smythe HA, Yunus MB et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum 1990; 33: 16072.
  • 4
    Crofford LJ, Rowbotham MC, Mease PJ et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 126473.
  • 5
    Arnold LM, Rosen A, Pritchett YL et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 515.
  • 6
    Arnold LM, Lu Y, Crofford LJ et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50: 297484.
  • 7
    Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum 2004; 51: 913.
  • 8
    Arnold LM, Hess EV, Hudson JI et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002; 112: 1917.
  • 9
    Goldenberg D, Mayskiy M, Mossey C et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996; 39: 18529.
  • 10
    Carette S, Bell MJ, Reynolds WJ et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. Arthritis Rheum 1994; 37: 3240.
  • 11
    Santandrea S, Montrone F, Sarzi-Puttini P et al. A double-blind crossover study of two cyclobenzaprine regimens in primary fibromyalgia syndrome. J Int Med Res 1993; 21: 7480.
  • 12
    Russell IJ, Fletcher EM, Michalek JE et al. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: a double-blind, placebo-controlled study. Arthritis Rheum 1991; 34: 55260.
  • 13
    Goldenberg DL. Fibromyalgia: treatment problems. J Musculoskelet Pain 1993; 1: 7181.
  • 14
    Dadabhoy D, Clauw DJ. Therapy insight: Fibromyalgia—a different type of pain needing a different type of treatment. Nat Clin Pract Rheum 2006; 2: 36472.
  • 15
    Dadabhoy D, Clauw DJ. Fibromyalgia: progress in diagnosis and treatment. Curr Pain Headache Rep 2005; 9: 399404.
  • 16
    Rao SG, Clauw DJ. The management of fibromyalgia. Drugs Today 2004; 40: 53954.
  • 17
    Bombardier CH, Buchwald D. Chronic fatigue, chronic fatigue syndrome, and fibromyalgia: disability and health-care use. Med Care 1996; 34: 92430.
  • 18
    White KP, Speechley M, Harth M, Ostbye T. The London Fibromyalgia Epidemiology Study: comparing the demographic and clinical characteristics in 100 random community cases of fibromyalgia versus controls. J Rheumatol 1999; 26: 157785.
  • 19
    Wolfe F, Anderson J, Harkness D et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997; 40: 156070.
  • 20
    Penrod JR, Bernatsky S, Adam V et al. Health services costs and their determinants in women with fibromyalgia. J Rheumatol 2004; 31: 13918.
  • 21
    Robinson RL, Birnbaum HG, Morley MA et al. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003; 30: 131825.
  • 22
    Hughes G, Martinez C, Myon E et al. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: An observational study based on clinical practice. Arthritis Rheum 2006; 54: 17783.
  • 23
    Boonen A, Van Den Heuvel R, Van Tubergen A et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylosis. Ann Rheum Dis 2005; 64: 396402.
  • 24
    World Health Organization. Cancer Pain Relief. Geneva, Switzerland: World Health Organization, 1996.
  • 25
    Brant JM. Cancer-related neuropathic pain. Nurse Pract Forum 1998; 9: 15462.
  • 26
    Kanner R. Diagnosis and management of neuropathic pain in patients with cancer. Cancer Invest 2001; 19: 32433.
  • 27
    George RM, Ahmedzai SH. The management of neuropathic pain in cancer: Clinical guidelines for the use of adjuvant analgesics. Indian J Cancer 2000; 37: 49.
  • 28
    Allen RR. Neuropathic pain in the cancer patient. Neuropathic Pain Syndr 1998; 16: 86987.
  • 29
    Katz N. Neuropathic pain in cancer and AIDS. Clin J Pain 2000; 16: S418.
  • 30
    Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988; 33: 1123.
  • 31
    Cohen KL, Harris S. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med 1987; 147: 14424.
  • 32
    Ripamonti C, Dickerson ED. Strategies for the treatment of cancer pain in the new millennium. Drugs 2001; 61: 95577.
  • 33
    Farrar JT, Portenoy RK. Neuropathic cancer pain: the role of adjuvant analgesics. Oncology 2001; 15: 143545.
  • 34
    Oster G, Berger A, Dukes E et al. Use of potentially inappropriate pain-related medications in older adults with painful neuropathic disorders. Am J Geriatr Pharmacother 2004; 2: 16370.
  • 35
    Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004; 5: 1439.
  • 36
    Berger A, Dukes E, Mercadante S, Oster G. Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain. Eur J Cancer Care 2006; 15: 13845.
  • 37
    SAS® Proprietary Software. Release 9.1. Cary, NC: SAS Institute Inc., 2004.
  • 38
    Oliver K, Cronan TA, Walen HR, Tomita M. Effects of social support and education on health care costs for patients with fibromyalgia. J Rheumatol 2001; 28: 27119.